Tuesday, August 5, 2025

Latest

PharmaTher Files With FDA For Orphan Drug Designation In Use Of Ketamine For ALS

PharmaTher Holdings (CSE: PHRM) this morning announced that it has filed with the US FDA for orphan drug designation as it works to further study the uses of ketamine. The latest filing pertains to the use of ketamine to treat Lou Gehrig’s disease, which is formally known as ALS, or amyotrophic lateral sclerosis.

Lou Gehrig’s disease is a neuromuscular disease, which currently has a life expectancy of just two to six years after initial diagnosis. The disease effectively causes upper and lower motor neurons to die, causing the brain to lose function of muscle movement. As the disease progresses patients lose voluntary muscle action, causing the inability to speak, eat, move and breathe. There is currently no cure for the disease.

Initial research conducted on ketamine has indicated that it has the potential to increase life expectancy of those impacted by the disease, slowing the progressive loss of muscle. Preclinical work has demonstrated that the compound preserves muscle function in advancing ALS, and improves life expectancy when administered early in the stages of muscles decline.

“Ketamine has tremendous potential for not only mental illness and pain disorders but also for neurodegenerative diseases such as ALS.  Our FDA orphan drug application for ketamine to treat this life-threatening disease complements our patent portfolio that aims to protect the proposed method of use and dosage claims of ketamine for ALS.  Although patent protection or market exclusivity could last beyond 2040, our intention to seek orphan drug designation is to leverage the expedited regulatory and clinical development incentives offered by the FDA for repurposed drugs in treating rare diseases.”

Fabio Chianelli, Chief Executive Officer of PharmaTher

PharmaTher Holdings last traded at $0.40 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

San Dimas: First Majestic Silver’s Sleeper Asset

New Gold Q2 Earnings: Record Free Cash Flow

STLLR Gold: The Tower Gold PEA

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

PharmaTher Receives FDA Approval For Ketamine Trial For Parkinson’s

PharmaTher Holdings (CSE: PHRM) has seen the US FDA approve the firms application for an...

Monday, May 17, 2021, 09:15:31 AM

PharmaTher To Raise $10.0 Million Via Institutional Investor Financing

PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with...

Friday, September 24, 2021, 08:28:12 AM

PharmaTher Files Patent For Use Of Ketamine In Type 2 Diabetes, Obesity

PharmaTher Holdings (CSE: PHRM) has expanded its patent portfolio. The company this morning announced the...

Tuesday, April 27, 2021, 07:54:44 AM

PharmaTher Licenses Patented Microneedle Delivery Tech For Ketamine

PharmaTher Inc (CSE: PHRM) this morning announced that it has entered into an exclusive worldwide...

Monday, February 1, 2021, 08:13:56 AM

Pharmather Enters Exclusive Arrangement For Psychedelic Delivery Tech

Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive license...

Thursday, October 22, 2020, 08:13:19 AM